精彩内容 近期，集采消息频传：江苏63个品种集采开标在即，国采1-8批接续来袭，浙江拟开展第六批集采，河南34个国采可替代、用量大、金额高的药品集采提 上日程，不乏顺铂注射剂等同为国家基药和医保甲类药品种，以及丙帕他莫注射剂等2024年在河南省公立医院终端销售额超8000万元的畅销药。国家重磅 会议释放新一轮国采信号，超140个品种满足7家及以上的企业竞争格局，齐鲁、远大、倍特等过评品种数惊人。 集采品种目录再优化，聚焦可替代、用量大、金额高 今年4月，河南省医保局发布《关于开展部分药品信息摸底工作的通知》（下文简称《通知》），拟对47个国采可替代药品进行摸底，并纳入参考监测清 单。 时隔约8个月（12月9日），《河南省牵头34种药品省际联盟采购规则要点（征求意见稿）》（下文简称《意见稿》）出炉，河南牵头拟对34个国采可替代 品种以及本省遴选的用量大、金额高药品开展新一轮带量集采（下文简称"河南省集采"）。 来源：河南省医保局 从集采品种上看，《意见稿》对比《通知》剔除了氨溴索口服液体剂、硝酸异山梨酯口服常释剂型、左西替利嗪口服液体剂、脂肪乳(C14-24)注射剂、普 拉洛芬滴眼剂、七氟烷吸入剂、卡铂注射剂、 ...

Core Insights - The U.S. Food and Drug Administration has approved an oral version of Novo Nordisk's weight-loss drug Wegovy, which could significantly increase access for millions of patients and enhance the company's market position [1] Company Summary - Novo Nordisk's Wegovy, previously available only in injectable form, is now approved in an oral formulation, potentially broadening its patient base [1] - The approval is expected to drive sales growth for Novo Nordisk, as oral medications are often preferred by patients over injections [1] Industry Summary - The weight-loss drug market is anticipated to expand with the introduction of oral formulations, catering to a larger demographic seeking weight management solutions [1] - Regulatory approvals like this one from the FDA are crucial for pharmaceutical companies aiming to innovate and meet patient needs in the competitive weight-loss sector [1]

Core Concept - The Dogs of the Dow strategy involves investing in the 10 highest-yielding stocks in the Dow Jones Industrial Average, based on the belief that these stocks are temporarily undervalued and may recover over time [1] Group 1: Dogs of the Dow Strategy - The strategy traditionally focuses on dividends and capital appreciation, but can be enhanced by incorporating options income through selling covered calls [2] - The current lineup of the 10 highest yielding stocks in the Dow includes Chevron, Merck & Company, Proctor & Gamble, Amgen, Coca-Cola Company, Nike, Unitedhealth Group, Home Depot, Johnson & Johnson [6] Group 2: Implementation of Covered Calls - Selling covered calls can potentially increase cash flow, reduce volatility, and create a more consistent income stream while maintaining the core Dogs of the Dow framework [2] - An example provided involves buying 100 shares of Verizon for approximately $4,000, with a call option generating $275 in premium, resulting in an income of 7.3% over 361 days [8]

Group 1 - The company expects to launch the weight-loss pill in the U.S. in early January [1]

Group 1: Novo Nordisk - The US FDA has approved an oral version of Novo Nordisk's Wegovy (semaglutide), marking it as the first GLP-1 oral treatment approved for obesity [3][4] - The approval was based on the OASIS 4 trial, which demonstrated a mean weight loss of 16.6% in adults who were obese or overweight with comorbidities when taking 25 mg of oral semaglutide daily [4] - Novo Nordisk's shares rose approximately 7% in premarket trading following the announcement [4] Group 2: Mercedes-Benz - Mercedes-Benz USA and parent company Daimler AG have agreed to a settlement of $149.6 million over diesel emissions allegations with 48 U.S. states, Puerto Rico, and the District of Columbia [4][5] - The settlement includes a payment of $120 million to the attorneys general, with an additional $29 million payment suspended pending the completion of a consumer relief program [6] Group 3: ByteDance - ByteDance plans to allocate approximately 160 billion yuan (~$22.77 billion) in capital expenditure for 2026, focusing primarily on AI infrastructure development [6][7] - About half of the budget, around 85 billion yuan, is aimed at advanced AI processors, while the remainder will support AI model training and data center expansions, including overseas facilities [7] - ByteDance is considering purchasing 20,000 NVIDIA H200 chips at about $20,000 per unit, which could lead to an increase in capital expenditure if access to more chips is granted [8]

Core Viewpoint - BeOne Medicines Ltd. will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 7:30 am PST, highlighting its commitment to oncology and innovative treatments [1]. Company Overview - BeOne Medicines is a global oncology company based in Switzerland, focused on discovering and developing innovative cancer treatments that are more accessible to patients worldwide [3]. - The company has a diverse pipeline that includes therapies for hematology and solid tumors, and it is enhancing development through internal capabilities and collaborations [3]. - BeOne Medicines employs nearly 12,000 colleagues across six continents, emphasizing its commitment to improving access to medicines for a larger patient population [3].

Core Insights - Novo Nordisk has received U.S. regulatory approval for its weight-loss pill, which may help the company recover from significant market capital loss and competition from Eli Lilly [1][2] - The approval comes after a challenging year for Novo, characterized by declining share prices, profit warnings, and slowing sales of its flagship product, Wegovy [2] Company Performance - Novo Nordisk's market capitalization has decreased from $650 billion in June last year to over $240 billion currently, indicating a loss of more than half its value [6] - The company's share price has significantly declined compared to its rivals over the past year [3] Competitive Landscape - Eli Lilly's Zepbound has surpassed Wegovy in U.S. prescriptions this year, marking a shift in the competitive dynamics of the obesity treatment market [2] - Novo was the first to market with Wegovy, approved in 2021, but has faced intensified competition since the launch of Zepbound in late 2023 [2] Financial Metrics - Novo's price-earnings ratio has returned to levels more in line with its peers, having previously commanded a significant premium [4] - The company has incurred rising costs due to investments in expanding manufacturing and sales capacity [5]

Novo Nordisk (NYSE: NVO) shares surged in pre-market and after-hours trading after the company secured U.S. regulatory approval for the world’s first GLP-1 weight-loss pill, a milestone that materially reshapes the obesity drug market.By press time, the stock was trading around $48.10, up about 7% in pre-market trading and having risen as much as 10% after hours, despite remaining nearly 50% lower year-to-date.NVO YTD stock price chart. Source: Google FinanceThe approval gives the Danish drugmaker a decisiv ...

The CNBC app, global market news in one place. Customizable sections and personalized alerts. Stocks tracking, interactive charts and market insights, all in your hands.Stay connected, stay informed, download the CNBC app today. Welcome to Sportbox Europe. I'm Sylvia Maro with Karen Show.And here are your headlines this Tuesday morning. Europe stock 600 hits a record intraday high with equities edging higher as the investors eye today's GDP print out of the United States and no order shares bounce as the dr ...

The approval gives Novo Nordisk a chance to regain ground lost to rival Eli Lilly. https://t.co/JDbETIToaq ...